Text
DDIVAT TECHNICAL
DDiVAT has already passed clinical trials and has been approved as a Class 1 medical device by the Greek National Drug Organization. The application for Smart-TVs is already available for the Android-TV operating system, and by March 2025, it will also be available for TiZEN and WebOS operating systems, covering 90% of installed television-sets in households across the EU and the USA.
In the second half of 2025, DDiVAT will integrate with smart home platforms Alexa & Google Home supporting smart lighting according to the user’s visual acuity needs
The DDiVAT clinical database is supported by the Computing Center of Democritus University of Thrace, fully complying with GDPR data protection guidelines.
The visual impairment risk calculation subsystem is continuously evolving in two key areas:
a) Further training of the underlying neural networks as they are continuously fed with clinical and demographic data of examinees.
b) Further integration with modern preventive actions for diseases with significant health, social, and economic impacts (diabetic retinopathy, age-related macular degeneration, amblyopia, dry-eye-disease, hypertensive retinopathy, etc.).